학술논문
Significant sE-Selectin levels reduction after 6 months of anti-TNF-α therapy in non-diabetic patients with moderate-to-severe psoriasis
Document Type
article
Author
Fernanda Genre; Susana Armesto; Alfonso Corrales; Raquel López-Mejías; Sara Remuzgo-Martínez; Trinitario Pina; Begoña Ubilla; Verónica Mijares; José Luis Martín-Varillas; Javier Rueda-Gotor; Virginia Portilla; Trinidad Dierssen-Sotos; Marcos Antonio González-López; María del Carmen González-Vela; Ricardo Blanco; Javier Llorca; José Luis Hernández; Miguel Ángel González-Gay
Source
Journal of Dermatological Treatment, Vol 28, Iss 8, Pp 726-730 (2017)
Subject
Language
English
ISSN
0954-6634
1471-1753
09546634
1471-1753
09546634
Abstract
Purpose: Psoriasis patients have high risk of atherosclerosis, characterized by endothelial dysfunction. We aimed to study the association of the endothelial activation biomarkers monocyte chemoattractant protein 1 (MCP-1), soluble (s) E-selectin and P-selectin with disease activity and severity in psoriasis patients treated with anti-TNF-α therapy. Also, to evaluate the relationship of metabolic syndrome features with these biomarkers and the effect of anti-TNF-α therapy on these molecules. Methods: Twenty-nine consecutive non-diabetic patients with moderate-to-severe psoriasis who underwent 6 months of anti-TNF-α-adalimumab therapy were studied. Metabolic and clinical evaluation was performed prior to anti-TNF-α treatment (time 0) and 6 months later. MCP-1, sE-selectin and sP-selectin serum levels were determined by ELISA. Results: Dyslipidemic and obese patients showed higher MCP-1 levels at month 6 from the onset of anti-TNF-α therapy (p = .05 and .01, respectively). sE-selectin positively correlated with pro-inflammatory molecules such as asymmetric dimethylarginine, sP-selectin and resistin at baseline and month 6 (p